BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield Management, Droia Oncology Ventures...
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...Polaris Partners, Asla Ventures, Pfizer Ventures, Executive Chairman: Luc Dochez Patents: None issued Lauren Martz, Senior Editor Droia Oncology Ventures Montis...
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...driver of cancer metastasis. Polaris Partners led the seed round on Tuesday with participation from Droia Oncology Ventures...
...Center Corporate partners: N/A Number of employees: 3 Funds raised: $12 million Investors: Polaris Partners, Droia Oncology Ventures...
BioCentury | Oct 15, 2019
Finance

Cyteir synthetic lethality compound prompts Novo to lead $40M investment

...submitting an IND for its next candidate before the company’s next offering. Existing investors Venrock, DROIA Oncology Ventures...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...rounds were led by GV, and had participation from Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA Oncology Ventures...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...In June, Frontier raised $67 million in a series A round led by Deerfield Management, Droia Oncology Ventures...
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...relatively early.” Luke Evnin, MPM Joining MPM in the round were co-leaders Deerfield Management and Droia Oncology Ventures...
BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...the pharma's Genentech Inc. unit. Tusk was founded in 2015 by CEO Luc Dochez and Droia Oncology Ventures...
...Business: Cancer Sandi Wong Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech...
BioCentury | Sep 28, 2018
Company News

Roche gains CD25 program via Tusk takeout

...the pharma's Genentech Inc. unit. Tusk was founded in 2015 by CEO Luc Dochez and Droia Oncology Ventures...
...majority shareholder. Sandi Wong Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech...
BioCentury | Mar 16, 2018
Financial News

Cyteir raises $29M series B

...on March 8. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures...
Items per page:
1 - 10 of 19
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield Management, Droia Oncology Ventures...
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...Polaris Partners, Asla Ventures, Pfizer Ventures, Executive Chairman: Luc Dochez Patents: None issued Lauren Martz, Senior Editor Droia Oncology Ventures Montis...
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...driver of cancer metastasis. Polaris Partners led the seed round on Tuesday with participation from Droia Oncology Ventures...
...Center Corporate partners: N/A Number of employees: 3 Funds raised: $12 million Investors: Polaris Partners, Droia Oncology Ventures...
BioCentury | Oct 15, 2019
Finance

Cyteir synthetic lethality compound prompts Novo to lead $40M investment

...submitting an IND for its next candidate before the company’s next offering. Existing investors Venrock, DROIA Oncology Ventures...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...rounds were led by GV, and had participation from Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA Oncology Ventures...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...In June, Frontier raised $67 million in a series A round led by Deerfield Management, Droia Oncology Ventures...
BioCentury | Jun 25, 2019
Finance

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...relatively early.” Luke Evnin, MPM Joining MPM in the round were co-leaders Deerfield Management and Droia Oncology Ventures...
BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...the pharma's Genentech Inc. unit. Tusk was founded in 2015 by CEO Luc Dochez and Droia Oncology Ventures...
...Business: Cancer Sandi Wong Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech...
BioCentury | Sep 28, 2018
Company News

Roche gains CD25 program via Tusk takeout

...the pharma's Genentech Inc. unit. Tusk was founded in 2015 by CEO Luc Dochez and Droia Oncology Ventures...
...majority shareholder. Sandi Wong Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech...
BioCentury | Mar 16, 2018
Financial News

Cyteir raises $29M series B

...on March 8. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures...
Items per page:
1 - 10 of 19